Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection
The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-r...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/full |
id |
doaj-5544ae135ad64856b321e886966e1db2 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Petros P. Sfikakis Petros P. Sfikakis Kleio-Maria Verrou Kleio-Maria Verrou Giannis Ampatziadis-Michailidis Ourania Tsitsilonis Dimitrios Paraskevis Efstathios Kastritis Evi Lianidou Paraskevi Moutsatsou Evangelos Terpos Ioannis Trougakos Vasiliki Chini Menelaos Manoloukos Panagiotis Moulos Panagiotis Moulos Georgios A. Pavlopoulos Georgios A. Pavlopoulos George Kollias George Kollias George Kollias Pantelis Hatzis Pantelis Hatzis Meletios A. Dimopoulos Meletios A. Dimopoulos |
spellingShingle |
Petros P. Sfikakis Petros P. Sfikakis Kleio-Maria Verrou Kleio-Maria Verrou Giannis Ampatziadis-Michailidis Ourania Tsitsilonis Dimitrios Paraskevis Efstathios Kastritis Evi Lianidou Paraskevi Moutsatsou Evangelos Terpos Ioannis Trougakos Vasiliki Chini Menelaos Manoloukos Panagiotis Moulos Panagiotis Moulos Georgios A. Pavlopoulos Georgios A. Pavlopoulos George Kollias George Kollias George Kollias Pantelis Hatzis Pantelis Hatzis Meletios A. Dimopoulos Meletios A. Dimopoulos Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection Frontiers in Immunology innate immunity anti-SARS-CoV2 antibody asympomatic RNAseq whole-blood |
author_facet |
Petros P. Sfikakis Petros P. Sfikakis Kleio-Maria Verrou Kleio-Maria Verrou Giannis Ampatziadis-Michailidis Ourania Tsitsilonis Dimitrios Paraskevis Efstathios Kastritis Evi Lianidou Paraskevi Moutsatsou Evangelos Terpos Ioannis Trougakos Vasiliki Chini Menelaos Manoloukos Panagiotis Moulos Panagiotis Moulos Georgios A. Pavlopoulos Georgios A. Pavlopoulos George Kollias George Kollias George Kollias Pantelis Hatzis Pantelis Hatzis Meletios A. Dimopoulos Meletios A. Dimopoulos |
author_sort |
Petros P. Sfikakis |
title |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection |
title_short |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection |
title_full |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection |
title_fullStr |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection |
title_full_unstemmed |
Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection |
title_sort |
blood transcriptomes of anti-sars-cov-2 antibody-positive healthy individuals who experienced asymptomatic versus clinical infection |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-10-01 |
description |
The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-related gene signatures reflecting baseline may differ between healthy individuals, with an equally robust antibody response, who experienced an entirely asymptomatic (n=17) versus clinical SARS-CoV-2 infection (n=15) in the past months (mean of 14 weeks). Among 12.789 protein-coding genes analysed, we identified six and nine genes with significantly decreased or increased expression, respectively, in those with prior asymptomatic infection relatively to those with clinical infection. All six genes with decreased expression (IFIT3, IFI44L, RSAD2, FOLR3, PI3, ALOX15), are involved in innate immune response while the first two are interferon-induced proteins. Among genes with increased expression six are involved in immune response (GZMH, CLEC1B, CLEC12A), viral mRNA translation (GCAT), energy metabolism (CACNA2D2) and oxidative stress response (ENC1). Notably, 8/15 differentially expressed genes are regulated by interferons. Our results suggest that subtle differences at baseline expression of innate immunity-related genes may be associated with an asymptomatic disease course in SARS-CoV-2 infection. Whether a certain gene signature predicts, or not, those who will develop a more efficient immune response upon exposure to SARS-CoV-2, with implications for prioritization for vaccination, warrant further study. |
topic |
innate immunity anti-SARS-CoV2 antibody asympomatic RNAseq whole-blood |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/full |
work_keys_str_mv |
AT petrospsfikakis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT petrospsfikakis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT kleiomariaverrou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT kleiomariaverrou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT giannisampatziadismichailidis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT ouraniatsitsilonis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT dimitriosparaskevis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT efstathioskastritis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT evilianidou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT paraskevimoutsatsou bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT evangelosterpos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT ioannistrougakos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT vasilikichini bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT menelaosmanoloukos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT panagiotismoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT panagiotismoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT georgiosapavlopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT georgiosapavlopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT georgekollias bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT pantelishatzis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT pantelishatzis bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT meletiosadimopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection AT meletiosadimopoulos bloodtranscriptomesofantisarscov2antibodypositivehealthyindividualswhoexperiencedasymptomaticversusclinicalinfection |
_version_ |
1716843441053237248 |
spelling |
doaj-5544ae135ad64856b321e886966e1db22021-10-05T06:07:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-10-011210.3389/fimmu.2021.746203746203Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical InfectionPetros P. Sfikakis0Petros P. Sfikakis1Kleio-Maria Verrou2Kleio-Maria Verrou3Giannis Ampatziadis-Michailidis4Ourania Tsitsilonis5Dimitrios Paraskevis6Efstathios Kastritis7Evi Lianidou8Paraskevi Moutsatsou9Evangelos Terpos10Ioannis Trougakos11Vasiliki Chini12Menelaos Manoloukos13Panagiotis Moulos14Panagiotis Moulos15Georgios A. Pavlopoulos16Georgios A. Pavlopoulos17George Kollias18George Kollias19George Kollias20Pantelis Hatzis21Pantelis Hatzis22Meletios A. Dimopoulos23Meletios A. Dimopoulos24Center of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceDepartment of Biology, National and Kapodistrian University of Athens (NKUA), Athens, GreeceDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Chemistry, National and Kapodistrian University of Athens (NKUA), Athens, GreeceDepartment of Clinical Biochemistry, School of Medicine, University General Hospital Attikon, NKUA, Haidari, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceJoint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece0Institute for Bioinnovation, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceInstitute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, GreeceCenter of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens Medical School, Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceThe reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-related gene signatures reflecting baseline may differ between healthy individuals, with an equally robust antibody response, who experienced an entirely asymptomatic (n=17) versus clinical SARS-CoV-2 infection (n=15) in the past months (mean of 14 weeks). Among 12.789 protein-coding genes analysed, we identified six and nine genes with significantly decreased or increased expression, respectively, in those with prior asymptomatic infection relatively to those with clinical infection. All six genes with decreased expression (IFIT3, IFI44L, RSAD2, FOLR3, PI3, ALOX15), are involved in innate immune response while the first two are interferon-induced proteins. Among genes with increased expression six are involved in immune response (GZMH, CLEC1B, CLEC12A), viral mRNA translation (GCAT), energy metabolism (CACNA2D2) and oxidative stress response (ENC1). Notably, 8/15 differentially expressed genes are regulated by interferons. Our results suggest that subtle differences at baseline expression of innate immunity-related genes may be associated with an asymptomatic disease course in SARS-CoV-2 infection. Whether a certain gene signature predicts, or not, those who will develop a more efficient immune response upon exposure to SARS-CoV-2, with implications for prioritization for vaccination, warrant further study.https://www.frontiersin.org/articles/10.3389/fimmu.2021.746203/fullinnate immunityanti-SARS-CoV2 antibodyasympomaticRNAseqwhole-blood |